Clinical Trial Update: Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

View source ↗

Summary

Clinical trial update from Ruijin Hospital outlines a mechanism investigation of R-CHOP alone or in combination with tucidinostat for treating diffuse large B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-CHOP regimen
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Ruijin Hospital | Conditions: Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma | Status: NOT_YET_RECRUITING